Abstract
Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies
Volume: 18 Issue: 37
Author(s): Adam Reich and Jacek C. Szepietowski
Affiliation:
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Abstract: Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Export Options
About this article
Cite this article as:
Reich Adam and C. Szepietowski Jacek, Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582405
DOI https://dx.doi.org/10.2174/138161212803582405 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Gene Expression Studies to Investigate Disease Mechanisms in Rheumatoid Arthritis: Does Angiogenesis Play a Role?
Current Rheumatology Reviews Merkel Cell Carcinoma – Current State and the Future
Current Cancer Therapy Reviews “Oxygen Supply” as Modulator of Aging Processes: Hypoxia and Hyperoxia Models for Aging Studies
Current Aging Science Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion
Current Medicinal Chemistry Regulation by IFN-α/IFN-γ Co-Formulation (HerberPAG<sup>®</sup>) of Genes Involved in Interferon-STAT-Pathways and Apoptosis in U87MG
Current Topics in Medicinal Chemistry Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Current Molecular Medicine The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Regulation of Drug Metabolism and Transporters
Current Drug Metabolism Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design